#### MOMENTA PHARMACEUTICALS INC

Form 4 April 20, 2015

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

Check this box if no longer subject to Section 16.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005
Estimated average

**OMB APPROVAL** 

respon 84

burden hours per response... 0.5

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \*\* Roach James M.

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol MOMENTA

PHARMACEUTICALS INC

(Check all applicable)

Director

(Last)

(First) (Middle)

3. Date of Earliest Transaction

\_X\_ Officer (give title

\_\_\_\_ 10% Owner \_\_\_\_ Other (specify

[MNTA]

(Month/Day/Year)

below) below)

Senior VP, Development and Chi

C/O MOMENTA 03/29/2015

PHARMACEUTICALS, INC., 675 WEST KENDALL STREET

(Street)

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person \_\_\_ Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

Person

CAMBRIDGE, MA 02142

| (City)                               | (State)                                 | (Zip) Tabl  | ble I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |                  |     |             |  |  |   |  |
|--------------------------------------|---|---|--|------------------|-----|-------------|--|--|---|--|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. 4. Securities<br>Transaction(A) or Disp<br>Code (Instr. 3, 4<br>(Instr. 8)  |                  |     |             | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
| Common<br>Stock                      | 03/29/2015                              |   | Code V D   | Amount 6,750 (1) | (D) | Price \$ 0  | (Instr. 3 and 4)<br>113,405  | D  |   |  |
| Common<br>Stock                      | 04/16/2015                              |   | M  | 50,000<br>(2)    | A   | \$ 7.41     | 163,405  | D  |   |  |
| Common<br>Stock                      | 04/16/2015                              |   | F  | 6,215<br>(3)     | D   | \$<br>17.08 | 157,190  | D  |   |  |
| Common<br>Stock                      | 04/16/2015                              |   | S  | 50,000<br>(2)    | D   | \$ 18.7     | 107,190  | D  |   |  |

#### Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of              | 2.  | 3. Transaction Date | 3A. Deemed              | 4. 5. Number of   |               | 6. Date Exercisable and |                    | 7. Title and Amount of |                                     |
|--------------------------|---|---------------------|-------------------------|---|---------------|-------------------------|--------------------|------------------------|-------------------------------------|
| Derivative               | Conversion  | (Month/Day/Year)    | Execution Date, if      | TransactionDerivative   |               | Expiration Date         |                    | Underlying Securities  |                                     |
| Security (Instr. 3)      | or Exercise<br>Price of<br>Derivative<br>Security |                     | any<br>(Month/Day/Year) | Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |               | (Month/Day/Y            | ear)               | (Instr. 3 and 4)       |                                     |
|                          |   |                     |                         | Code V  | (A) (D        | Date<br>Exercisable     | Expiration<br>Date | Title                  | Amount<br>or<br>Number<br>of Shares |
| Option to purchase stock | \$ 7.41   | 04/16/2015          |                         | M   | 50,000<br>(2) | 02/22/2012              | 02/22/2018         | Common<br>Stock        | 50,000                              |

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Roach James M. C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE, MA 02142

Senior VP, Development and Chi

## **Signatures**

Plan, as amended.

/s/ Marie T. Washburn as attorney in fact 04/20/2015

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents a decrease of 6,750 shares of restricted common stock, \$0.0001 par value per share, pursuant to the related restricted stock (1) agreement, as amended, between Mr. Roach and the Company. The shares were awarded pursuant to the Company's 2004 Stock Incentive
- (2) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2014.
  - Represents the number of shares of restricted common stock returned to the company to meet minimum tax liability requirements,
- (3) pursuant to the related restricted stock agreement, as amended, between Mr. Roach and the Company. The shares were awarded pursuant to the Company's 2004 Stock Incentive Plan, as amended.

Reporting Owners 2

### Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.